Skip to content

Author

David Holland

We have 2 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B013: Preclinical evaluation of NAMPT inhibitors with pyrimidine agonist antimetabolites floxuridine and 5-FU in rhabdomyosarcoma

While therapeutic advances have improved survival across pediatric malignancies, these gains have yet to be fully realized for patients with rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma. Our previous studies have shown that RMS is highly sensitive to targeting of nicotinamide phosphoribosyltr...

Jamie Gudyka, C. Yeung, Senna Munnikuysen et al. · 0 citations
Open access Aug 2026

Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma

NB is identified as a highly NAMPT inhibitor-sensitive pediatric solid tumor and NAMPT-dependent NAD + biosynthesis as a targetable metabolic vulnerability in this disease is established.

Sophia Varriano, Amy Yu, Abantika Chakraborty et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.